Eli Lilly and Co
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY2409021 Formulations and the Effect of Food
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2409021 Test-Med Formulation (medium particle size)Drug: LY2409021 Reference FormDrug: LY2409021 Test-High Formulation (high particle size)Drug: LY2409021 Test-Low Formulation (low particle size)
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT01354496
- Locations
- πΈπ¬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your person physician., Singapore, Singapore
A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 383
- Registration Number
- NCT01352507
- Locations
- π¨π³
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xi'An, China
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Biological: IMC-CS4
- First Posted Date
- 2011-05-03
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT01346358
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈOhio State University Medical Center, Columbus, Ohio, United States
πΊπΈUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 17
- Registration Number
- NCT01341457
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan
A Phase 1 Study of LY2787106 in Cancer and Anemia
- Conditions
- Anemia
- Interventions
- Drug: LY2787106Dietary Supplement: Iron Supplementation
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT01340976
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States
A Study of LY2495655 in Healthy Subjects
- Conditions
- Healthy Volunteer
- Interventions
- Drug: LY2495655Drug: Placebo
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT01341470
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States
A Study of LY2951742 in Healthy Volunteers
- Conditions
- Migraines
- Interventions
- Drug: PlaceboDrug: LY2951742
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 63
- Registration Number
- NCT01337596
- Locations
- π§πͺ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium
A First Human Study of a Ferroportin Antibody
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboDrug: LY2928057
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01330953
- Locations
- πΈπ¬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 51
- Registration Number
- NCT01324388
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of LY2828360 in Patients With Osteoarthritic Knee Pain
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01319929
- Locations
- π©π°
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark